Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

From population to neuron: exploring common mediators for metabolic problems and mental illnesses

Abstract

Major mental illnesses such as schizophrenia (SZ) and bipolar disorder (BP) frequently accompany metabolic conditions, but their relationship is still unclear, in particular at the mechanistic level. We implemented an approach of “from population to neuron”, combining population-based epidemiological analysis with neurobiological experiments using cell and animal models based on a hypothesis built from the epidemiological study. We characterized high-quality population data, olfactory neuronal cells biopsied from patients with SZ or BP, and healthy subjects, as well as mice genetically modified for insulin signaling. We accessed the Danish Registry and observed (1) a higher incidence of diabetes in people with SZ or BP and (2) higher incidence of major mental illnesses in people with diabetes in the same large cohort. These epidemiological data suggest the existence of common pathophysiological mediators in both diabetes and major mental illnesses. We hypothesized that molecules associated with insulin resistance might be such common mediators, and then validated the hypothesis by using two independent sets of olfactory neuronal cells biopsied from patients and healthy controls. In the first set, we confirmed an enrichment of insulin signaling-associated molecules among the genes that were significantly different between SZ patients and controls in unbiased expression profiling data. In the second set, olfactory neuronal cells from SZ and BP patients who were not pre-diabetic or diabetic showed reduced IRS2 tyrosine phosphorylation upon insulin stimulation, indicative of insulin resistance. These cells also displayed an upregulation of IRS1 protein phosphorylation at serine-312 at baseline (without insulin stimulation), further supporting the concept of insulin resistance in olfactory neuronal cells from SZ patients. Finally, Irs2 knockout mice showed an aberrant response to amphetamine, which is also observed in some patients with major mental illnesses. The bi-directional relationships between major mental illnesses and diabetes suggest that there may be common pathophysiological mediators associated with insulin resistance underlying these mental and physical conditions.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Relations between risk of diabetes and severe mental illnesses.
Fig. 2: Tyrosine phosphorylation of IRS2 in olfactory neuronal cells derived from SZ and BP patients.
Fig. 3: Response of Irs2 knockout mice after methamphetamine administration.

References

  1. 1.

    Weissman MM, Brown AS, Talati A. Translational epidemiology in psychiatry: linking population to clinical and basic sciences. Arch Gen Psychiatry. 2011;68:600–8.

    PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Morris JN. Uses of epidemiology. 3rd ed. Edinburgh: Churchill Livingstone; 1975.

  3. 3.

    Torrey EF, Torrey BB, Peterson MR. Seasonality of schizophrenic births in the United States. Arch Gen Psychiatry. 1977;34:1065–70.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 2010;167:261–80.

    PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Curtis VA, van Os J, Murray RM. The Kraepelinian dichotomy: evidence from developmental and neuroimaging studies. J Neuropsychiatry Clin Neurosci. 2000;12:398–405.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Neale BM, Sklar P. Genetic analysis of schizophrenia and bipolar disorder reveals polygenicity but also suggests new directions for molecular interrogation. Curr Opin Neurobiol. 2015;30:131–8.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15:166–74.

    PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Liao CH, Chang CS, Wei WC, Chang SN, Liao CC, Lane HY, et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res. 2011;126:110–6.

    PubMed  Article  Google Scholar 

  9. 9.

    Bai YM, Su TP, Chen MH, Chen TJ, Chang WH. Risk of developing diabetes mellitus and hyperlipidemia among patients with bipolar disorder, major depressive disorder, and schizophrenia: a 10-year nationwide population-based prospective cohort study. J Affect Disord. 2013;150:57–62.

    PubMed  Article  Google Scholar 

  10. 10.

    Enger C, Jones ME, Kryzhanovskaya L, Doherty M, McAfee AT. Risk of developing diabetes and dyslipidemia among adolescents with bipolar disorder or schizophrenia. Int J Adolesc Med Health. 2013;25:3–11.

    PubMed  Article  Google Scholar 

  11. 11.

    Benros ME, Eaton WW, Mortensen PB. The epidemiologic evidence linking autoimmune diseases and psychosis. Biol Psychiatry. 2014;75:300–6.

    PubMed  Article  Google Scholar 

  12. 12.

    Schwartz TL, Nihalani N, Jindal S, Virk S, Jones N. Psychiatric medication-induced obesity: a review. Obes Rev. 2004;5:115–21.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  13. 13.

    Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, et al. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry. 2009;194:434–8.

    PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Garcia-Rizo C, Kirkpatrick B, Fernandez-Egea E, Oliveira C, Bernardo M. Abnormal glycemic homeostasis at the onset of serious mental illnesses: a common pathway. Psychoneuroendocrinology. 2016;67:70–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Greenhalgh AM, Gonzalez-Blanco L, Garcia-Rizo C, Fernandez-Egea E, Miller B, Arroyo MB, et al. Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naive patients with nonaffective psychosis. Schizophr Res. 2017;179:57–63.

    PubMed  Article  Google Scholar 

  16. 16.

    Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53:441–9.

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    Munk-Jorgensen P, Mortensen PB. The Danish psychiatric central register. Dan Med Bull. 1997;44:82–4.

    CAS  PubMed  Google Scholar 

  18. 18.

    Carstensen B, Kristensen JK, Marcussen MM, Borch-Johnsen K. The national diabetes register. Scand J Public Health. 2011;39:58–61.

    PubMed  Article  Google Scholar 

  19. 19.

    Evgrafov OV, Armoskus C, Wrobel BB, Spitsyna VN, Souaiaia T, Herstein JS, et al. Gene expression in patient-derived neural progenitors implicates WNT5A signaling in the etiology of schizophrenia. Biol Psychiatry. 2020;88:236–47.

  20. 20.

    Kano S, Colantuoni C, Han F, Zhou Z, Yuan Q, Wilson A, et al. Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia. Mol Psychiatry. 2013;18:740–2.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Sumitomo A, Yukitake H, Hirai K, Horike K, Ueta K, Chung Y, et al. Ulk2 controls cortical excitatory-inhibitory balance via autophagic regulation of p62 and GABAA receptor trafficking in pyramidal neurons. Hum Mol Genet. 2018;27:3165–76.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Wu J, Tseng YD, Xu CF, Neubert TA, White MF, Hubbard SR. Structural and biochemical characterization of the KRLB region in insulin receptor substrate-2. Nat Struct Mol Biol. 2008;15:251–8.

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Emdal KB, Pedersen AK, Bekker-Jensen DB, Lundby A, Claeys S, De Preter K, et al. Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma. Sci Signal. 2018;11.

  24. 24.

    Valverde AM, Burks DJ, Fabregat I, Fisher TL, Carretero J, White MF, et al. Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes. Diabetes. 2003;52:2239–48.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Taguchi A, Wartschow LM, White MF. Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science. 2007;317:369–72.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Kozuka T, Omori Y, Watanabe S, Tarusawa E, Yamamoto H, Chaya T, et al. miR-124 dosage regulates prefrontal cortex function by dopaminergic modulation. Sci Rep. 2019;9:3445.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  27. 27.

    Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong S, et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci USA. 2007;104:14501–6.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Niwa M, Jaaro-Peled H, Tankou S, Seshadri S, Hikida T, Matsumoto Y, et al. Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids. Science. 2013;339:335–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Sumitomo A, Horike K, Hirai K, Butcher N, Boot E, Sakurai T, et al. A mouse model of 22q11.2 deletions: molecular and behavioral signatures of Parkinson’s disease and schizophrenia. Sci Adv. 2018;4:eaar6637.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Hall DA, Stanis JJ, Marquez, Avila H, Gulley JM. A comparison of amphetamine- and methamphetamine-induced locomotor activity in rats: evidence for qualitative differences in behavior. Psychopharmacology. 2008;195:469–78.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  31. 31.

    Lavoie J, Sawa A, Ishizuka K. Application of olfactory tissue and its neural progenitors to schizophrenia and psychiatric research. Curr Opin Psychiatry. 2017;30:176–83.

    PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Rhie SK, Schreiner S, Witt H, Armoskus C, Lay FD, Camarena A, et al. Using 3D epigenomic maps of primary olfactory neuronal cells from living individuals to understand gene regulation. Sci Adv. 2018;4:eaav8550.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Namkung H, Lee BJ, Sawa A. Causal inference on pathophysiological mediators in psychiatry. Cold Spring Harb Symp Quant Biol. 2018;83:17–23.

    PubMed  Article  Google Scholar 

  34. 34.

    White MF. IRS2 integrates insulin/IGF1 signalling with metabolism, neurodegeneration and longevity. Diabetes Obes Metab. 2014;16 Suppl 1:4–15.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab. 2009;296:E581–91.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    White MF. Insulin signaling in health and disease. Science. 2003;302:1710–1.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Costello DA, Claret M, Al-Qassab H, Plattner F, Irvine EE, Choudhury AI, et al. Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity. PLoS ONE. 2012;7:e31124.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    Howell KR, Floyd K, Law AJ. PKBgamma/AKT3 loss-of-function causes learning and memory deficits and deregulation of AKT/mTORC2 signaling: Relevance for schizophrenia. PLoS ONE. 2017;12:e0175993.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  39. 39.

    Wang W, Tanokashira D, Fukui Y, Maruyama M, Kuroiwa C, Saito T, et al. Serine phosphorylation of IRS1 correlates with Abeta-unrelated memory deficits and elevation in Abeta level prior to the onset of memory decline in AD. Nutrients. 2019;11.

  40. 40.

    Martin ED, Sanchez-Perez A, Trejo JL, Martin-Aldana JA, Cano Jaimez M, Pons S. et al. IRS-2 deficiency impairs NMDA receptor-dependent long-term potentiation. Cereb Cortex. 2012;22:1717–27.

    PubMed  Article  Google Scholar 

  41. 41.

    Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S. et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 1998;391:900–4.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Moulton CD, Pickup JC, Ismail K. The link between depression and diabetes: the search for shared mechanisms. Lancet Diabetes Endocrinol. 2015;3:461–71.

    PubMed  Article  Google Scholar 

  43. 43.

    Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 1987;91:415–33.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Crawley JN. What’s wrong with my mouse?: Behavioral phenotyping of transgenic and knockout mice. 2nd ed: Hoboken, New Jersey: Wiley-Liss; 2007. p. 544.

  45. 45.

    Zhu J, Zhang S, Cai H, Wang C, Yu Y. Common and distinct functional stability abnormalities across three major psychiatric disorders. Neuroimage Clin. 2020;27:102352.

    PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Clementz BA, Sweeney JA, Hamm JP, Ivleva EI, Ethridge LE, Pearlson GD, et al. Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry. 2016;173:373–84.

    PubMed  Article  Google Scholar 

  47. 47.

    Axelsson AS, Tubbs E, Mecham B, Chacko S, Nenonen HA, Tang Y, et al. Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes. Sci Transl Med. 2017;9.

  48. 48.

    Sedlak TW, Nucifora LG, Koga M, Shaffer LS, Higgs C, Tanaka T, et al. Sulforaphane augments glutathione and influences brain metabolites in human subjects: a clinical pilot study. Mol Neuropsychiatry. 2018;3:214–22.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  49. 49.

    Singh K, Connors SL, Macklin EA, Smith KD, Fahey JW, Talalay P, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci USA. 2014;111:15550–5.

    CAS  PubMed  Article  Google Scholar 

  50. 50.

    Shiina A, Kanahara N, Sasaki T, Oda Y, Hashimoto T, Hasegawa T, et al. An open study of sulforaphane-rich broccoli sprout extract in patients with schizophrenia. Clin Psychopharmacol Neurosci. 2015;13:62–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Perkins DO, Jeffries CD, Do KQ. Potential roles of redox dysregulation in the development of schizophrenia. Biol Psychiatry. 2020;88:326–36.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Houghton CA. Sulforaphane: Its “Coming of Age” as a clinically relevant nutraceutical in the prevention and treatment of chronic disease. Oxid Med Cell Longev. 2019;2019:2716870.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  53. 53.

    Alvarez-Arellano L, Gonzalez-Garcia N, Salazar-Garcia M, Corona JC. Antioxidants as a potential target against inflammation and oxidative stress in attention-deficit/hyperactivity disorder. Antioxidants. 2020;9.

  54. 54.

    Joseph JJ, Golden SH. Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus. Ann NY Acad Sci. 2017;1391:20–34.

    PubMed  Article  Google Scholar 

  55. 55.

    Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Pharmacol Ther. 2012;136:82–93.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068–83.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  57. 57.

    Lee SH, Zabolotny JM, Huang H, Lee H, Kim YB. Insulin in the nervous system and the mind: functions in metabolism, memory, and mood. Mol Metab. 2016;5:589–601.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Plum L, Schubert M, Bruning JC. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab. 2005;16:59–65.

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    Landek-Salgado MA, Faust TE, Sawa A. Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Mol Psychiatry. 2016;21:10–28.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Badiola N, Suarez-Calvet M, Lleo A. Tau phosphorylation and aggregation as a therapeutic target in tauopathies. CNS Neurol Disord Drug Targets. 2010;9:727–40.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 2009;118:53–69.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  62. 62.

    Rajkumar AP, Horsdal HT, Wimberley T, Cohen D, Mors O, Borglum AD, et al. Endogenous and antipsychotic-related risks for diabetes mellitus in young people with schizophrenia: A Danish Population-Based Cohort Study. Am J Psychiatry. 2017;174:686–94.

    PubMed  Article  Google Scholar 

Download references

Acknowledgements

We thank Yukiko Y. Lema for organizing the manuscript and figures, Drs. Melissa A. Landek-Salgado and Nao J. Gamo for critical reading of the manuscript. AS and KI are supported by the National Institute of Mental Health MH-105660 and Maryland Stem Cell Research Fund. AS is also supported by MH-094268 Silvio O. Conte center, MH-092443, and MH-107730, as well as foundation grants from Stanley, S-R/RUSK, BBRF. TS is supported by Kakenhi from the Ministry of Education, Culture, Sports, Science and Technology in Japan, and was funded in part by the Takeda and Kyoto University Basic and Clinical Research Project for CNS Drugs (supported in part by Takeda Pharmaceutical Co. Ltd). TML was supported by an unrestricted grant from the Stanley Medical Research Institute. PBM was supported by grants from the Danish Strategic Research Council, the Faculty of Social Sciences at Aarhus University, the Lundbeck Foundation, the Stanley Medical Research Institute, and a European Research Council advanced grant (GA 2948338). WWE was supported by NIMH grant 1R34MH007760-01.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Takeshi Sakurai or Akira Sawa.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Takayanagi, Y., Ishizuka, K., Laursen, T.M. et al. From population to neuron: exploring common mediators for metabolic problems and mental illnesses. Mol Psychiatry (2020). https://doi.org/10.1038/s41380-020-00939-5

Download citation

Search

Quick links